Journal of Immunology Research

Clinical Study

Platelets and Inflammatory Markers in Patients with Gastric Cancer

Table 3

The concentration of IL-6 and IL-23 in patients suffering from gastric cancer—early gastric cancer, E (E1 before surgery, E2 after surgery), advanced cancer with metastasis to lymph nodes, A (A1 before surgery, A2 after surgery), and metastatic tumor, M (M1 before surgery, M2 after surgery) and in normal donors (C).


	IL-6	IL-23
	X ± SD	X ± SD

Study group	21.28 ± 6.34	10.89 ± 5.46
E1	E1 : C	E1 : C
	P < 0.01 *	P < 0.05 *

Study group	10.86 ± 8.93	3.88 ± 2.59
E2	E1 : E2	E1 : E2
	n.s.	P<0.01 *

Study group	11.51 ± 8.44	9.46 ± 8.81
A1	A1 : C	A1 : C
	P < 0.001 *	P < 0.001 *

Study group	20.42 ± 10.68	10.80 ± 8.24
A2	A1 : A2	A1 : A2
	n.s.	n.s.

Study group	8.44 ± 5.63	5.94 ± 4.70
M1	M1 : C	M1 : C
	P < 0.001 *	n.s.

Study group	15.26 ± 14.73	3.05 ± 2.47
M2	M1 : M2	M1 : M2
	n.s.	n.s.

Control group
C	2.45 ± 1.44	5.21 ± 3.65

Statistically significant when P < 0.05.